Survodutide Research, Specifications & Scientific Information

Introduction

Survodutide is Boehringer Ingelheim's entry into the multi-agonist field, and its design premise is a natural peptide rather than a chemical hypothesis. Oxyntomodulin is a gut hormone that activates the glucagon receptor and the GLP-1 receptor simultaneously; survodutide is a synthetic peptide built to do the same thing with a plasma half-life measured in days rather than minutes ^[1].

Adding glucagon receptor agonism to an incretin agonist is the pharmacologically interesting choice and the historically difficult one, because glucagon raises blood glucose. What makes survodutide's record worth reading is that its clinical programme tested the combination against exactly the objection: its phase 2 trial in type 2 diabetes ran against an open-label semaglutide arm, and its most substantial results are in liver disease, where glucagon receptor agonism has a mechanistic rationale that incretin agonism alone does not.

This page is a reference record. It sets out what has been published about survodutide's structure, its receptor pharmacology, and the preclinical and clinical literature, with every source resolved against PubMed, Crossref or ClinicalTrials.gov at the time the page was built. It describes research. It does not describe use in people or animals, and it carries no guidance of any kind on handling the material.

What Is Survodutide?

Survodutide is an investigational synthetic peptide, developed by Boehringer Ingelheim under the code BI 456906 and first described in the peer-reviewed literature in 2022 ^[1]. It is not an approved medicine in the United States and has not been approved by the U.S. Food and Drug Administration for any indication.

Structurally it belongs to the glucagon–secretin peptide superfamily. Functionally it is a dual receptor agonist, meaning one molecule binds and activates two distinct class B1 G protein-coupled receptors — but the pair matters as much as the number. Survodutide's pair is the glucagon receptor and the GLP-1 receptor. Tirzepatide is also a dual agonist and its pair is the GIP receptor and the GLP-1 receptor, with no glucagon receptor activity at all. The two compounds are described with the same word and are not doing the same thing.

Clinical development has moved quickly: a phase 2 trial in type 2 diabetes and a phase 2 range-finding trial in obesity both reported in 2024 ^{[2, 3]}, a phase 2 trial in metabolic dysfunction-associated steatohepatitis with histological endpoints reported the same year ^[4], and the phase 3 SYNCHRONIZE programme has begun reporting ^{[5, 6]}.

Survodutide Specifications

The FDA/NCATS Global Substance Registration System records survodutide under UNII 2ALA66NS64 as a substance with two subunits: a 29-residue chain written HXQGTFTSDYSKYLDERAAKDFIKWLESA, and a short GSGSGG segment. The letter X in the first string is a placeholder for a residue that has no single-letter representation — the position-2 substitution that this family of peptides uses to block dipeptidyl peptidase-4 cleavage — so the string cannot be read as if every letter were a standard amino acid. The register also carries structural modifications for this substance, and its own calculated mass for the bare backbone is about 3300 g/mol against the approximately 4232 g/mol carried by PubChem CID 171378821 for the complete molecule; the roughly 930-dalton difference is the modification chemistry. The published discovery paper describes that chemistry directly: survodutide is an acylated peptide carrying a C18 fatty acid as the half-life-extending principle intended to support once-weekly administration in humans. Any figure on this page is a reference value: the certificate of analysis supplied with a laboratory order is the record for a given lot.

Values that a public register does not carry are shown as not publicly characterised rather than estimated. Identifiers are reference values; the certificate of analysis supplied with a laboratory order is the record for a given lot.

How Does Survodutide Work?

Both of survodutide's targets are class B1 G protein-coupled receptors and both couple through Gs to raise intracellular cyclic AMP. They sit in different tissues and drive different processes, so activating them together is not equivalent to activating either one harder.

The GLP-1 receptor arm is the familiar incretin pharmacology: receptors on pancreatic islet cells and at sites in the central nervous system, whose activation modulates glucose-dependent insulin secretion, slows gastric emptying and reduces calorie intake.

The glucagon receptor arm is the departure. Glucagon receptor signalling in the liver raises whole-body metabolic rate and alters hepatic lipid handling — and, unopposed, raises blood glucose, which is why glucagon agonism was avoided in diabetes work for decades. The premise of a dual agonist is that the incretin arm holds glucose in check while the glucagon arm contributes something the incretin arm cannot reach.

Natural oxyntomodulin does precisely this and is useless as a medicine for the usual reason: it is cleared within minutes. Survodutide's contribution is to reproduce the receptor profile on a backbone that persists, using a C18 fatty acid as the half-life-extending principle ^[1].

Survodutide Mechanism of Action

In vitro research

Functional agonism at both receptors was characterised in cell-based assays before any animal work, and the discovery paper reports it as the compound's defining property: potent activity at the glucagon receptor and at the GLP-1 receptor in a single molecule ^[1].

The molecule that carries that profile is an acylated peptide with a C18 fatty acid attached as the half-life-extending principle, chosen to support once-weekly administration in humans ^[1]. That is the same class of albumin-binding modification used by semaglutide and retatrutide, and it is the reason a peptide with oxyntomodulin's receptor profile can be given weekly when oxyntomodulin itself cannot.

An ex vivo bioactivity assay was used alongside the cell assays to confirm that the dual activity survived in tissue rather than only in transfected cell lines ^[1].

Analytical characterisation of supplied material is a separate exercise from receptor pharmacology and relies on liquid chromatography with mass spectrometric detection against a reference standard rather than on any biological assay.

What Is Survodutide Being Researched For?

Registered clinical research on survodutide has covered, in order of how far each has progressed:

• Obesity and overweight without diabetes — phase 2 range-finding and a phase 3 trial that has reported ^{[3, 5]}.
• Metabolic dysfunction-associated steatohepatitis and steatotic liver disease — a phase 2 trial with liver biopsies and a phase 3 trial with imaging endpoints, both reported ^{[4, 6]}.
• Type 2 diabetes mellitus — a phase 2 trial with an open-label active comparator, and a phase 3 trial in participants with obesity and type 2 diabetes ^[2].
• Cardiovascular outcomes in obesity — a registered phase 3 trial in more than five thousand participants ^[11].

Each of those is research into a pharmaceutical product candidate, conducted by its sponsor under a registered protocol. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Human Research on Survodutide

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Phase 2 range-finding in obesity

Population. 387 participants enrolled and 386 treated, aged 18–75 with body-mass index 27 kg/m² or above and without diabetes, at 43 centres in 12 countries ^{[3, 8]}.

Endpoint and duration. Primary endpoint the percentage change in body mass from baseline to week 46, in a randomised, double-blind, placebo-controlled design with 20 weeks of escalation followed by 26 weeks of maintenance ^[3].

Result. Mean changes in body mass at week 46, by planned treatment, were −6.2% (95% CI −8.3 to −4.1) in the 0.6 mg group, −12.5% (−14.5 to −10.5) at 2.4 mg, −13.2% (−15.3 to −11.2) at 3.6 mg and −14.9% (−16.9 to −13.0) at 4.8 mg, against −2.8% (−4.9 to −0.7) for placebo ^[3].

Adverse events. Adverse events occurred in 281 of 309 participants receiving survodutide (91%) against 58 of 77 on placebo (75%); these were primarily gastrointestinal in 232 of 309 (75%) against 32 of 77 (42%) ^[3].

Limitations. Only 233 of 386 treated participants (60.4%) completed the 46-week treatment period — a completion rate that is the most important number in the trial and is easy to overlook beside the efficacy figures. A range-finding trial by design, not powered for outcomes.

Phase 2 in MASH and fibrosis

Population. 293 randomised participants who received at least one administration, adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stage F1 to F3 ^{[4, 9]}.

Endpoint and duration. Primary endpoint histological improvement in MASH with no worsening of fibrosis, over 48 weeks comprising a 24-week rapid escalation phase and a 24-week maintenance phase. Secondary endpoints included a decrease in liver fat content of at least 30% and biopsy-assessed improvement in fibrosis by at least one stage ^[4].

Result. Improvement in MASH without worsening of fibrosis occurred in 47% of the 2.4 mg group, 62% of the 4.8 mg group and 43% of the 6.0 mg group, against 14% on placebo, with a quadratic curve as the best-fitting model, P < 0.001. A decrease in liver fat content of at least 30% occurred in 63%, 67% and 57% against 14% on placebo. Improvement in fibrosis by at least one stage occurred in 34%, 36% and 34% against 22% ^[4].

Adverse events. More frequent with survodutide than with placebo: nausea (66% against 23%), diarrhoea (49% against 23%) and vomiting (41% against 4%). Serious adverse events occurred in 8% against 7% ^[4].

Limitations. The response curve is not monotonic — the 6.0 mg group performed worse than the 4.8 mg group on the primary endpoint — which the authors handle by fitting a quadratic model and which is worth reading as a real feature of the data rather than noise. The fibrosis endpoint separated from placebo by much less than the MASH endpoint did, and fibrosis is the component that determines outcome in liver disease. Phase 2, 48 weeks.

Phase 2 in type 2 diabetes, with an active comparator

Population. 413 randomised participants aged 18–75 with type 2 diabetes, glycated haemoglobin 7.0–10.0%, body-mass index 25–50 kg/m², on a background of metformin; 411 treated ^{[2, 7]}.

Endpoint and duration. Primary endpoint the absolute change from baseline in glycated haemoglobin after 16 weeks. Six survodutide groups, placebo, and an open-label semaglutide arm up to 1.0 mg weekly ^[2].

Result. From a mean baseline of 64.7 ± 9.2 mmol/mol (8.07 ± 0.84%), adjusted mean reductions ranged from −9.92 mmol/mol (−0.91%) in the lowest group to −18.72 mmol/mol (−1.71%) in the group escalated to 1.8 mg weekly. The reduction in the 0.9 mg group, −15.95 mmol/mol (−1.46%), was similar to that in the semaglutide arm, −16.07 mmol/mol (−1.47%). Change in body mass fell with increasing amounts to −8.7% (95% CI −10.1 to −7.3) in the highest group, against −5.3% (−6.6 to −4.1) for semaglutide ^[2].

Adverse events. Reported for 77.8% of survodutide participants, mainly gastrointestinal, against 52.5% on placebo and 52.0% on semaglutide. The authors state that the relationship between the amount administered and gastrointestinal events could be mitigated by slower escalation ^[2].

Limitations. Sixteen weeks, which is short for a glycaemic endpoint and much too short for anything else. The semaglutide arm was open-label and was escalated only to 1.0 mg, not to the higher amounts used in obesity trials, so the comparison is against a specific regimen rather than against the comparator at its maximum.

SYNCHRONIZE-1 — phase 3 in adults with obesity without diabetes

Population. 725 participants with a body-mass index of 30 or higher, or 27 or higher with at least one obesity-related complication other than diabetes. Mean age 47.1 years, 40.6% men, mean body-mass index 37.9, mean body mass 108.8 kg ^{[5, 10]}.

Endpoint and duration. Two primary endpoints at week 76: the percent change in body mass, and a reduction of at least 5% from baseline. The primary analysis used a treatment-regimen estimand that incorporates early discontinuation, use of protocol-prohibited obesity medications, and a prolonged escalation period ^[5].

Result. At week 76, mean change in body mass was −12.2% (95% CI −13.6 to −10.8) in the 3.6 mg group, −13.0% (−14.4 to −11.6) in the 6.0 mg group and −5.4% (−6.9 to −4.0) with placebo. Reductions of at least 5% occurred in 72.6%, 71.9% and 46.3% respectively, P < 0.001 for all comparisons with placebo ^[5].

Adverse events. The most common were gastrointestinal symptoms, typically mild to moderate, in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group. No deaths were reported ^[5].

Limitations. The placebo group's −5.4% is large for a placebo arm and narrows the treatment difference correspondingly; so is the 46.3% of placebo participants reaching a 5% reduction. Seventy-six weeks, with an anthropometric primary endpoint rather than a clinical outcome, and the two survodutide groups differing from each other by less than one percentage point.

SYNCHRONIZE-MASLD — phase 3 in obesity with at-risk steatotic liver disease

Population. 216 adults (131 female, 85 male) with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, defined by evidence of liver inflammation or fibrosis on noninvasive tests or by biopsy-confirmed steatohepatitis. Randomised 2:1 to survodutide 6.0 mg weekly (n = 146) or placebo (n = 70) ^{[6, 12]}.

Endpoint and duration. Co-primary endpoints at week 48: a reduction of at least 30% in liver fat content measured by magnetic resonance imaging proton density fat fraction, and the percentage change in body mass ^[6].

Result. Both co-primary endpoints were met. A reduction in liver fat content of at least 30% occurred in 84.2% of survodutide participants against 24.3% on placebo on the efficacy estimand, P < 0.0001, and in 68.5% against 28.6% on the treatment-regimen estimand, P < 0.0001. Mean percentage change in body mass was −12.2% against −1.0% on the efficacy estimand and −8.7% against −1.4% on the treatment-regimen estimand, P < 0.0001 for both ^[6].

Adverse events. Most frequently gastrointestinal, commonly occurring during escalation, and generally mild to moderate ^[6].

Limitations. The authors state two directly: a 48-week duration, and recruitment limited to the United States and Spain. The primary liver endpoint is imaging rather than histology, and the gap between the efficacy and treatment-regimen estimands — 84.2% against 68.5% — is a measure of how much of the result depends on participants remaining on treatment.

Preclinical Research on Survodutide

Animal research

The mouse work reported with the compound's discovery did two things, and the second is more unusual than the first.

The first is a comparison. In mice, pharmacologically effective amounts of survodutide produced greater body-mass reductions than maximally effective amounts of the GLP-1 receptor agonist semaglutide ^[1]. The authors attribute that difference to two contributions working together: an increase in metabolic rate and a reduction in food intake.

The second is a separation of the two receptor arms in the living animal, which is harder than it sounds because both receptors affect overlapping readouts. GLP-1 receptor engagement was demonstrated through glucose tolerance, food intake and gastric emptying tests. Glucagon receptor engagement was demonstrated through hepatic nicotinamide N-methyltransferase messenger RNA expression and through circulating biomarkers — amino acids and fibroblast growth factor-21 — that respond to glucagon receptor signalling and not to GLP-1 receptor signalling. The dual activity was then confirmed genetically, using GLP-1 receptor knockout mice and transgenic reporter mice ^[1].

That genetic confirmation is the part worth carrying. A compound can produce a larger effect than a comparator for many reasons that have nothing to do with the second receptor; a knockout mouse is one of the few ways to show that the second receptor is actually doing the work.

Findings described in this section were observed in animals. Mouse models of diet-induced obesity are standard preclinical tools and are poor predictors of the size of human results in this field specifically. Nothing in them establishes anything about humans.

Current Research Status

Status as of September 22, 2026. This block is rendered from maintained fields, not from prose, so it cannot go stale in one place and stay current in another.

Survodutide vs Related Compounds

The distinction between survodutide and the compounds it is usually set beside is which receptors each engages, and nothing else is stated here.

Receptor agonism

Survodutide — GCGR and GLP-1R. Tirzepatide — GIPR and GLP-1R. Retatrutide — GIPR, GLP-1R and GCGR. Semaglutide — GLP-1R alone.

Dual is not one category

Survodutide and tirzepatide are both described as dual agonists and share only one of their two targets. The second receptor differs, and the second receptor is what the pharmacology turns on.

Other glucagon-containing agonists

Mazdutide and pemvidutide are also GCGR/GLP-1R dual agonists in clinical development; retatrutide adds GIPR to the same pair. Direct comparative trials between these compounds are limited.

Duration chemistry

Survodutide uses a C18 fatty acid as its half-life-extending principle ^[1], the same albumin-binding strategy used by semaglutide and retatrutide.

Regulatory position

Semaglutide and tirzepatide are active ingredients of approved pharmaceutical products in the United States. Survodutide, retatrutide and pemvidutide are investigational. Approval is specific to a product and an indication and does not extend across a pharmacological class.

No comparison of effect between these compounds is made on this page. Where head-to-head trials exist they are registered, and their results belong to the papers that report them.

Chemical & Molecular Characteristics

The FDA/NCATS Global Substance Registration System records survodutide under UNII 2ALA66NS64 as a substance with two subunits: a 29-residue chain written HXQGTFTSDYSKYLDERAAKDFIKWLESA, and a short GSGSGG segment.

Three points qualify that record, and they are why this section sits separately from the specification table above.

The X is not an amino acid. It is the register's placeholder for a residue with no single-letter representation. The position it occupies — second from the N-terminus — is the position that dipeptidyl peptidase-4 cleaves after, and substituting a non-standard residue there is the standard solution in this family of peptides. Reading the string as if every letter were a standard amino acid would misdescribe the molecule at the position that matters most for its stability.

The register's backbone is not the whole molecule. The register carries structural modifications for this substance, and its own calculated mass for the bare backbone is approximately 3300 g/mol against the approximately 4232 g/mol carried by PubChem compound identifier 171378821. The roughly 930-dalton difference is the modification chemistry — principally the C18 fatty acid and its linker, which the discovery paper describes explicitly as the half-life-extending principle ^[1].

The identifiers agree where they overlap. CAS registry number 2805997-46-8 is carried by both PubChem and the Global Substance Registration System, and the molecular formula C192H289N47O61 is carried by both for the complete molecule. That consistency is worth noting because it is not universal in this category.

Frequently Asked Questions

Scientific References

1. Zimmermann T, Thomas L, Baader-Pagler T, et al.. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Molecular metabolism; 2022. PMID 36356832 doi:10.1016/j.molmet.2022.101633
2. Blüher M, Rosenstock J, Hoefler J, et al.. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia; 2024. PMID 38095657 doi:10.1007/s00125-023-06053-9
3. le Roux CW, Steen O, Lucas KJ, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial The lancet. Diabetes & endocrinology; 2024. PMID 38330987 doi:10.1016/S2213-8587(23)00356-X
4. Sanyal AJ, Bedossa P, Fraessdorf M, et al.. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis The New England journal of medicine; 2024. PMID 38847460 doi:10.1056/NEJMoa2401755
5. le Roux CW, Wharton S, Startseva E, et al.. Survodutide Once Weekly for the Treatment of Adults with Obesity The New England journal of medicine; 2026. PMID 42253238 doi:10.1056/NEJMoa2600751
6. Kaplan LM, Startseva E, le Roux CW, et al.. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nature medicine; 2026. PMID 42252333 doi:10.1038/s41591-026-04479-3
7. A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. 2020. NCT04153929
8. A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight 2021. NCT04667377
9. A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) 2021. NCT04771273
10. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight 2023. NCT06066515
11. A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) 2023. NCT06077864
12. A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) 2024. NCT06309992

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.